Summit Therapeutics (SMMT) Non-Current Deferred Tax Liability (2016 - 2020)
Summit Therapeutics filings provide 6 years of Non-Current Deferred Tax Liability readings, the most recent being $2.1 million for Q3 2020.
- Quarterly Non-Current Deferred Tax Liability changed N/A to $2.1 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Sep 2020, changed N/A year-over-year, with the annual reading at $2.1 million for FY2019, N/A changed from the prior year.
- Non-Current Deferred Tax Liability hit $2.1 million in Q3 2020 for Summit Therapeutics, up from -$2.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.1 million in Q3 2020 and bottomed at -$3.4 million in Q1 2018.
- Average Non-Current Deferred Tax Liability over 5 years is -$1.3 million, with a median of -$2.0 million recorded in 2019.
- The largest annual shift saw Non-Current Deferred Tax Liability surged 195.8% in 2016 before it crashed 581.41% in 2018.
- Summit Therapeutics' Non-Current Deferred Tax Liability stood at -$811000.0 in 2016, then rose by 7.52% to -$750000.0 in 2017, then tumbled by 195.38% to -$2.2 million in 2018, then grew by 9.46% to -$2.0 million in 2019, then skyrocketed by 205.1% to $2.1 million in 2020.
- Per Business Quant, the three most recent readings for SMMT's Non-Current Deferred Tax Liability are $2.1 million (Q3 2020), -$2.2 million (Q1 2020), and -$2.0 million (Q4 2019).